The pharmacological interest in GPR183 stems from the implication of the receptor and its endogenous ligands in a variety of diseases like B cell malignancies, inflammatory/autoimmune diseases and metabolic diseases.[6] Moreover, it was recently shown to regulate interferons and bacterial growth during Mycobacterium tuberculosis infection.[7]. The gene discussed is GPR183; the disease is Other metabolic disease.